Journal article

Age-specific differences in the in vitro anticoagulant effect of Bivalirudin in healthy neonates and children compared to adults

Natasha Letunica, Xavier Busuttil-Crellin, Jessica Cowley, Paul Monagle, Vera Ignjatovic

THROMBOSIS RESEARCH | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2020

Abstract

Bivalirudin is a reversible direct thrombin inhibitor that inhibits both bound and free thrombin and binds to the active (catalytic) and fibrinogen-binding sites of thrombin, with high affinity and specificity. Off-label use of bivalirudin in the paediatric population has increased, as an alternative to heparin, particularly in the setting of anticoagulation for patients undergoing coronary bypass surgery (CPB), extracorporeal life support (ECLS) and those on ventricular assist devices (VAD). This study aimed to determine the age-specific in vitro effect of bivalirudin in children compared to adults. Age-specific pools (neonates, ≤2 years, >2 to 5 years, 6 to 10 years, 11 to 17 years and Adu..

View full abstract